A PEPTIDE MOIETY OF HUMAN Α1-ACID GLYCOPROTEIN IS RECOGNIZED BY THE
HEMOGLOBIN Β-CHAIN ON MOUSE LIVER PARENCHYMAL CELLS

Ayaka Suenaga¹, Koji Nishi¹, Hisakazu Komori¹, Mari Kikuchi¹, Nao Uehara¹, Naoko Fukunaga¹, Kazuaki Matsumoto¹, Hiroshi Watanabe¹,², Keisuke Nakajou¹, Toru Maruyama¹,² and Masaki Otagiri¹,³
¹Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences and
²Center for Clinical Pharmaceutical Sciences, School of Pharmacy, Kumamoto University,
Kumamoto, Japan; ³Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto,
Japan
E-mail: asuenaga@gpo.kumamoto-u.ac.jp

ABSTRACT

Human α1-acid glycoprotein (AGP), a serum glycoprotein, is known to have anti-inflammatory activity. We recently reported that AGP was mainly incorporated into the liver in mice via a receptor-mediated pathway, although the mechanism for this was largely unknown. The objective of this study was to identify the specific cellular surface protein that recognizes the peptide moiety of AGP. Pharmacokinetic studies of ¹¹¹In-AGP and recombinant glycan-deficient ¹¹¹In-AGP (rAGP) in mice demonstrated that both AGPs are mainly distributed to the liver and kidney, but hepatic and renal uptake clearance of rAGP was higher than that for AGP. Hepatic uptake of rAGP was inhibited in the presence of a 100-fold excess of unlabeled AGP, indicating that the hepatic uptake of rAGP shared a common route with that of AGP and that it recognized the peptide moiety of AGPs. In ligand blotting analyses using crude cellular membrane fraction of mice liver, a band corresponding to a 16 kDa protein was observed to bind to both AGPs. Interestingly, MALDI/TOFMS and Western blotting analyses indicated that this 16 kDa protein is the hemoglobin β-chain (HBB). It therefore appears that HBB is associated with the hepatic uptake of AGP via a direct interaction with its peptide moiety.